Ligand grows in cancer again with $100m Apeiron takeover

Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.

Apeiron starts mid-stage trial of drug that blocks coronavir...